Research Seminar with Boshen Jiao, PhD, MPH
A Framework for Assessing the Value of Expanding First-Line Treatment Choices
Open to Penn Affiliates
Health care payers frequently implement insurance coverage policies to restrict the use of high-cost, new first-line treatments. Although traditional cost-effectiveness analysis (CEA) serves as a tool to inform these policy decisions by comparing a new treatment with the standard of care, this method may fail to consider several essential real-world factors. These factors include heterogeneous treatment effects, individualized patient preferences, and costs associated with policy implementation. This talk will present a new CEA framework that addresses these real-world complexities. The framework’s applicability will be illustrated with a case study examining first-line treatments for metastatic prostate cancer.
Co-sponsored with the Division of General Internal Medicine.
Please note: In-person attendance at this event is preferred. Virtual access will be provided to registrants who are unable to be on campus.
Speaker
Boshen Jiao, PhD, MPH
Postdoctoral research fellow, Harvard T.H. Chan School of Public Health
Boshen Jiao, PhD, MPH, is a postdoctoral research fellow at Harvard T.H. Chan School of Public Health. His research primarily focuses on comparative effectiveness and cost-effectiveness analysis, health outcomes research, and value-based drug pricing and insurance design. His work aims to provide insights for medical decision-making and inform health policies across various disease areas through health economics and outcomes research (HEOR). He has a notable record of publications in health economics and clinical journals, and his work has been covered in media on multiple occasions. Dr. Jiao has received several academic awards, including the Best Podium Presentation Award from ISPOR—The Professional Society for Health Economics and Outcomes Research, and the Lee Lusted Prize from the Society for Medical Decision Making. He earned his PhD in HEOR from the University of Washington School of Pharmacy.